On June 3, the Associated Press issued an article stating that China is using its mature domestic vaccine industry to advance its vaccination program at an alarming rate, a speed that almost no other country in the world can achieve.
The full text is excerpted as follows:
Last month, China received 100 million doses of COVID-19 vaccine in just five days. China is now doing something that almost no other country in the world can do: using its extensive influence and mature domestic vaccine industry to advance vaccination at an alarming rate.
As of Wednesday (June 2), China has received more than 704 million doses of vaccine, of which nearly half were issued in May. According to data from the Oxford University online research website “Our World in Data”, about 1.9 billion doses of vaccines have been vaccinated globally, and about one-third of them are from China.
According to the 7-day rolling average data of the website, China now has an average of approximately 19 million doses per day, which is equivalent to about one dose for every Italian every three days. The United States, which has a population of about one-fourth of China, could only receive 3.4 million doses a day when the vaccine was promoted at full speed in April.
In China, the voice of encouraging vaccination comes from all corners of society. The company provides vaccines to employees, the school encourages students and staff to vaccinate, and local government staff are also concerned about the vaccinations of residents.
In the capital, Beijing, vaccination is very easy. There are hundreds of vaccination spots throughout the city. “Mobile vaccination vehicles” are parked in areas with high traffic, including downtowns and shopping malls.
China also pays attention to vaccinating overseas Chinese citizens. Globally, China has benefited more than 500,000 overseas citizens through its “Spring Seed Operation”.
As for vaccine production, analysts and industry insiders said that China’s vaccine manufacturers are unlikely to encounter problems with the scale of production. Kexing Pharmaceutical and Sinopharm have produced most of the vaccines distributed in China, and both vaccines have received emergency use authorization from the World Health Organization. Both companies are actively increasing production, building new factories, and transforming existing factories to deal with the new crown pneumonia. Kexing said the annual production capacity could reach 2 billion doses, while Sinopharm said the annual production capacity would reach 3 billion doses.
In addition, Chinese vaccine companies basically do not rely on imported products in the production process. This is a huge advantage when many countries are competing for the same raw materials, which means that China can avoid the Serum Institute of India’s encounter. Due to the dependence on imports of certain raw materials from the United States, the institute’s production was once in trouble.